QL1706 in Combination With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma

NCT06852456 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Iparomlimab and Tuvonralimab (QL1706)Injection
DRUG: Paclitaxel
DRUG: Cisplatin

Sponsor

Qilu Pharmaceutical Co., Ltd.